All results

24 results for randomized double blind multiple dose placebo controlled study evaluate safety

• JNT-517

  The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD)…

  Ages

  18 Years - 65 Years

  Sexes

  All

• MOM-M281-006

  The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA). The study consists…

  Ages

  18 Years - N/A

  Sexes

  All

• Mino-Lok

  This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that…

  Ages

  12 Years - N/A

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• PROTECT Extension Study

  The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in…

  Ages

  9 Years - 19 Years

  Sexes

  All

• Piomic COMS_03

  The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic…

  Ages

  22 Years - 90 Years

  Sexes

  All

• RAISE

  This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status…

  Ages

  12 Years - N/A

  Sexes

  All

• RECOVER VITAL

  This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community…

  Ages

  18 Years - N/A

  Sexes

  All

• ReCePI

  The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on…

  Ages

  11 Years - N/A

  Sexes

  All

• TETON

  Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from…

  Ages

  40 Years - N/A

  Sexes

  All